French trial opens in diabetes-diet drug scandal

French trial opens in diabetes-diet drug scandal (AP)
Jacques Servier, center, founder of Servier Laboratories, sits with his lawyers during the opening of the trial at Nanterre's court house, outside Paris, Monday, May 14, 2012. A French court has opened the first of trials over a drug for diabetes commonly used to lose weight and suspected of killing at least 500 people. The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine, benfluorex _ removed from the market in 2009 after being found to thicken heart valves. (AP Photo/Michel Euler)

(AP) -- The first French trial has begun over a diabetes drug that was also used to lose weight and is suspected in the deaths of at least 500 people.

The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine called - which was taken off the market in 2009 after being found to thicken .

However, another investigation is underway and lawyers for Servier were arguing Monday against holding the current trial claiming that the laboratory could be judged twice on the same grounds.

The nature of benfluorex was allegedly hidden to obtain approval for the drug, first marketed in 1976. So far, charges have been filed against seven people, including drugmaker chief Jacques Servier.


Explore further

Diabetes drug may have killed 500 in France: authorities

©2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: French trial opens in diabetes-diet drug scandal (2012, May 14) retrieved 28 November 2020 from https://medicalxpress.com/news/2012-05-french-trial-diabetes-diet-drug-scandal.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments